News Reader.info

ABSTRACT We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to

the EBMT. The median age was 39 years (range, 3–69), and stem cell source was bone marrow (_n_=31), or peripheral blood progenitor cells (_n_=30), or the combination of both (_n_=4). The

primary disease was solid tumors (_n_=37), Hodgkin's disease (_n_=13), non-Hodgkin's lymphoma (_n_=10), acute lymphoblastic leukemia (_n_=2) or myeloproliferative syndromes

(_n_=3). The types of MDS were as follows: RAEB (_n_=1; 2%), RAEB-t (_n_=3; 5%), or AML (_n_=56; 87%). The median time between diagnosis and transplantation was 5 months (range, 3–86). The

Kaplan–Meier estimates of the probability of 3-year overall and disease-free survival were 35% (95% CI: 21–49%) and 32% (95% CI: 18–45%), respectively. The median leukocyte engraftment was

faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9–26) vs 29 (range, 11–67) days (_P_<0.001). The cumulative incidence of relapse was 58%

(95% CI: 44–72%) and of treatment-related mortality 12% (95% CI: 6–38%). Lower relapse rate was seen in patients transplanted in first complete remission (CR1 vs non-CR1: 3 years: 48 vs 89%;

_P_=0.05). Furthermore, age beyond 40 years resulted in a higher treatment-related mortality (47 vs 7%; _P_=0.01). In a multivariate analysis, transplantation in CR1 age as well as their

interaction influenced overall survival significantly. Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR1 and

of younger age. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS ALLOGENEIC BLOOD OR MARROW TRANSPLANTATION WITH HAPLOIDENTICAL DONOR AND POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN PATIENTS

WITH MYELOFIBROSIS: A MULTICENTER STUDY Article 18 October 2021 WHICH LOWER RISK MYELODYSPLASTIC SYNDROMES SHOULD BE TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION? Article

13 July 2020 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULTS WITH THERAPY-RELATED ACUTE MYELOID LEUKAEMIA: A RETROSPECTIVE MULTICENTRE STUDY ON BEHALF OF THE SFGM-TC Article 31

August 2023 REFERENCES * Levine EG, Bloomfield CD . Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. _Semin Oncol_ 1992; 19: 47–84. CAS 

Google Scholar  * Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from

the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. _Br J Haematol_ 1999; 106: 1020–1026. Article  CAS  Google Scholar  * Smith SM,

Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of

Chicago series. _Blood_ 2003; 102: 43–52. Article  CAS  Google Scholar  * Linassier C, Barin C, Calais G, Letortorec S, Bremond JL, Delain M et al. Early secondary acute myelogenous leukemia

in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. _Ann Oncol_ 2000; 11: 1289–1294. Article  CAS  Google Scholar  *

Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C . Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem

cell support in patients with potentially curable malignancies. _J Cancer Res Clin Oncol_ 1998; 124: 207–214. Article  CAS  Google Scholar  * Felix CA . Secondary leukemias induced by

topoisomerase-targeted drugs. _Biochim Biophys Acta_ 1998; 1400: 233–255. Article  CAS  Google Scholar  * Pedersen-Bjergaard J, Andersen MK, Johansson B . Balanced chromosome aberrations in

leukemias following chemotherapy with DNA-topoisomerase II inhibitors. _J Clin Oncol_ 1998; 16: 1897–1898. Article  CAS  Google Scholar  * Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen

G, Byrsting K . Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. _Blood_ 1990; 76: 1083–1091. CAS  PubMed  Google Scholar  *

Picozzi Jr VJ, Swanson GF, Morgan R, Hecht F, Greenberg PL . 13-_cis_ retinoic acid treatment for myelodysplastic syndromes. _J Clin Oncol_ 1986; 4: 589–595. Article  Google Scholar  *

Ballen KK, Antin JH . Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. _Hematol Oncol Clin North Am_ 1993; 7: 477–493. Article  CAS  Google Scholar  *

Kantarjian HM, Estey EH, Keating MJ . Treatment of therapy-related leukemia and myelodysplastic syndrome. _Hematol Oncol Clin North Am_ 1993; 7: 81–107. Article  CAS  Google Scholar  *

Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the

literature. _J Clin Oncol_ 1993; 11: 2370–2379. Article  CAS  Google Scholar  * Yakoub-Agha I, de La SP, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation

for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients – report of the French society of bone marrow transplantation. _J Clin Oncol_ 2000;

18: 963–971. Article  CAS  Google Scholar  * de Witte T, van Biezen A, Hermans J, Labopin M, Runde V, Or R et al. Autologous bone marrow transplantation for patients with myelodysplastic

syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. _Blood_ 1997; 90: 3853–3857.

CAS  PubMed  Google Scholar  * de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic

syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). _Br J Haematol_

2000; 110: 620–630. Article  CAS  Google Scholar  * Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ et al. Bone marrow transplantation for therapy-related myelodysplasia:

comparison with primary myelodysplasia. _Bone Marrow Transplant_ 1997; 20: 737–743. Article  CAS  Google Scholar  * Goldstone AH, Burnett AK, Avivi I . Secondary acute myeloid leukemia has a

worse outcome in MRC trials. _Blood_ 2002; 100: 88a (abstract 322). Google Scholar  * Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T . Karyotype is an independent prognostic

parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with _de novo_ AML. _Leukemia_ 2004; 18: 120–125. Article 

CAS  Google Scholar  * Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C . Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. _J Clin Oncol_ 2004; 22:

2510–2511. Article  Google Scholar  * Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP et al. A prospective study of autologous bone marrow or peripheral blood stem cell

transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. _Leukemia_ 1999;

13: 524–529. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS We thank the physicians mentioned in the appendix for referring their patients data to the EBMT Chronic

Leukaemia Working Party registry. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany N Kröger & A Zander *

Department of Medical Statistics, Leiden University, Leiden, The Netherlands R Brand & A van Biezen * Service d'Hematologie, Hopital Jean Minjoz, Besancon, France J-Y Cahn *

Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel S Slavin * Institut Paoli Calmettes, Marseille, France D Blaise * Department of Hematology,

Hospital Santa Creu I Sant Pau, Barcelona, Spain J Sierra * Department of Haematology and Oncology, University of Leipzig, Leipzig, Germany D Niederwieser * Division of Haematology,

University Hospital, Nijmegen, The Netherlands T de Witte Authors * N Kröger View author publications You can also search for this author inPubMed Google Scholar * R Brand View author

publications You can also search for this author inPubMed Google Scholar * A van Biezen View author publications You can also search for this author inPubMed Google Scholar * J-Y Cahn View

author publications You can also search for this author inPubMed Google Scholar * S Slavin View author publications You can also search for this author inPubMed Google Scholar * D Blaise

View author publications You can also search for this author inPubMed Google Scholar * J Sierra View author publications You can also search for this author inPubMed Google Scholar * A

Zander View author publications You can also search for this author inPubMed Google Scholar * D Niederwieser View author publications You can also search for this author inPubMed Google

Scholar * T de Witte View author publications You can also search for this author inPubMed Google Scholar CONSORTIA FOR THE MYELODYSPLASTIC SYNDROMES SUBCOMMITTEE OF THE CHRONIC LEUKAEMIA

WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) CORRESPONDING AUTHOR Correspondence to N Kröger. APPENDIX APPENDIX RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Kröger, N., Brand, R., van Biezen, A. _et al._ Autologous stem cell transplantation for therapy-related acute myeloid leukemia and

myelodysplastic syndrome. _Bone Marrow Transplant_ 37, 183–189 (2006). https://doi.org/10.1038/sj.bmt.1705226 Download citation * Received: 10 June 2005 * Revised: 19 September 2005 *

Accepted: 19 September 2005 * Published: 21 November 2005 * Issue Date: 01 January 2006 * DOI: https://doi.org/10.1038/sj.bmt.1705226 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative KEYWORDS * autologous stem cell transplantation * therapy-related * myelodysplastic syndrome * acute myelogenous leukemia